UPDATE: Morgan Stanley Reiterates On athenahealth Following HQ Visit

In a report published Tuesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on

, but removed the $192.00 price target. In the report, Morgan Stanley noted, “Margins [are] in focus. Management goal is to achieve annual gross margin expansion as existing products gain critical mass and new services are launched. Collector margins are already at mid-70% range, representing a proxy for gross margin expansion opportunity as product suite reaches critical mass. Adjusting for R&D and S&M growth initiatives and gross margin expansion points to long-term steady state operating margin opportunity of 30%.” athenahealth closed on Monday at $121.07.